|
Pharmaceutical Technology rounds up the key readouts from the 2026 Digestive Disease Week conference held in Chicago.
|
 |
|
The FDA granted breakthrough therapy designation to TERN-701 for adults with Philadelphia chromosome-positive CML without the T315I mutation.
|
|
|
Non-viral gene therapies may ease some safety, pricing and manufacturing challenges linked to viral vectors, but experts say both approaches will still have a place.
|
|
|
This acquisition marks UCB’s second foray into the TCE space – closely following a blockbuster licensing deal with TCE specialist, Antengene.
|
|
|
Langlara is manufactured by Sunshine Lake Pharma, part of the HEC Group and commercialised in the US via Lanexa Biologics.
|
|
